Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.
CONCLUSIONS: RFSF related to organ function rarely deteriorate unless directly involved with underlying malignancy. Most RFSF do not prevent patients from having SST, nor increase dose reductions, especially in treatment-naïve/phase III trial-ineligible patients. Those with RFSF of poor PS, rapid PD, and aLFT from LM are less suitable for SST. Careful broadening of trial eligibility is warranted.
PMID: 31266008 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tiu C, Loh Z, Gan CL, Gan H, John T, Hawkes E Tags: Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colon Cancer | Colorectal Cancer | Liver | Melanoma | Pancreas | Pancreatic Cancer | Skin Cancer | Study | Switzerland Health | Urology & Nephrology